The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure

C. Davidon
M.A., M.B., M.R.C.P.

L. Burkinshaw
B.Sc., Ph.D.

D. B. Morgan
M.D., M.R.C.Path.

Departments of Medicine, Medical Physics and Chemical Pathology, General Infirmary, Leeds

Summary
Extra potassium supplements, spironolactone or amiloride were given for 5 months to forty-nine patients with heart failure who were taking furosemide and were in a steady state. Plasma potassium increased with all three treatments but there was no significant increase in total body potassium or red cell potassium. These findings together with other studies suggest that patients with heart failure taking diuretics do not have a significant depletion of body potassium.

Introduction
Potassium depletion is generally accepted as one of the hazards of long-term treatment with potent diuretics in patients with heart failure, and these patients are therefore usually also given either potassium supplements or one of the potassium-sparing diuretics. The authors recently measured the total body potassium (TBK) of patients with chronic heart disease with a total body radiation counter (Davidson et al., 1976). The TBK in the patients with heart disease was not significantly different from the TBK in a group of healthy subjects. Moreover, among the patients with heart disease there was no difference between those who were taking diuretics and those who were not, and in those on diuretics there was no difference between those taking small doses of potassium supplements and those taking large doses.

These findings contrasted with previous reports in the literature, and did not support the view that potassium depletion was a complication of long-term diuretic therapy. Nevertheless, it could be argued that a cross-sectional study is an insensitive approach since it depends on the comparison of a group of patients with a group of controls; a more sensitive approach would be to study serial changes in individual patients. Ideally such a study should be carried out from the time the patients start diuretics but this is difficult logistically and as far as the authors know it has not been done. Alternatively one can attempt to correct any deficit in body potassium in patients already established on treatment by giving extra potassium supplements or a potassium-retaining diuretic. If potassium depletion is present, these changes in treatment should cause an increase in TBK, even in a patient whose TBK is reduced but still lies within the normal range. Surprisingly this approach has only rarely been used in heart failure (De Deuchaisnes, Busset and Collet, 1961; White, 1970; Davidson and Gillebrand, 1973).

A group of patients with heart failure have been studied who had been taking a constant dose of furosemide and potassium supplements for at least 6 months. The potassium supplements were either increased to 48 mmol/day or replaced by spironolactone or amiloride. The dose of furosemide was kept constant throughout the study. The potassium status of the three treatment groups was assessed at monthly intervals for 5 months after the change of treatment.

Patients
The patients in this study came from a larger cross-sectional study of patients with heart failure (Davidson et al., 1976). Sixty-six patients who agreed to join the study were allocated to one of three treatment groups using random tables. Six patients were subsequently excluded from the potassium group because they were already taking 48 mmol of potassium or more per day. Eleven patients did not finish the trial; six required an increased dose of diuretic, three defaulted and two died from myocardial infarction. The final analysis was therefore based on a total of forty-nine patients; thirteen patients had their potassium supplements increased to 48 mmol/day; sixteen took spironolactone (100 mg/day) and twenty took amiloride (20 mg/day). The patients in the spironolactone and amiloride groups stopped their potassium supplements. The increase in potassium supplements in
the potassium group (given Slow K) was on average 25 mmol/day (range 8–40 mmol/day). Clinical
details of the patients are shown in Table 1.
The patients were seen at least once, but usually
twice, before their treatment was changed and then
five times at monthly intervals. At each visit the
patients were asked about symptoms and the side
effects of treatment, and their TBK, plasma potas-
sium, red cell potassium and 24-hr urine potassium
excretion were measured. Details of these techniques
are given elsewhere (Davidson et al., 1976). Chest
X-rays were taken at the beginning and end of the
study. The total duration of the study was 18
months.

Results
Table 2 shows that the plasma, electrolytes, urea
and creatinine were the same on average in the three
groups before treatment was changed. The average
TBK differed between the groups, but there were
also differences in age and weight. The observed
TBK was compared with the TBK predicted from
sex, age, weight, height and skin fold thicknesses
(Davidson et al., 1976). There was a small apparent
deficit of TBK in each group (205, 79 and 183 mmol
respectively).

None of the patients had any clinical or radio-
logical deterioration during the study. Twelve
patients (two on potassium supplements, three on
spironolactone, seven on amiloride) had transient
epigastric discomfort or nausea when they changed
treatment. In three patients (two spironolactone,
one amiloride) these symptoms persisted until the
end of the study. Two patients in the spironolactone
group had persistent gynaecomastia.

Figure 1 shows the changes in plasma potassium,
urinary potassium excretion and TBK in the three
groups of patients. The results have been calculated
as the difference from the mean value before the
treatment was changed. Plasma potassium increased
at first in all groups by 0.1–0.2 mmol/l but the rise
was not sustained in the potassium group. Urinary
potassium excretion increased by the expected 20
mmol/day in the potassium group and decreased
by the same amount in the other two groups who
stopped their potassium supplements when they
changed treatment. There were no significant
changes in TBK.

In order to summarize the changes in the other
measurements, the values before treatment have
been compared with the values at the fourth month
of treatment; the values at 4 months were represen-
tative of the values in the latter part of the study.
There were small falls in body weight and blood
pressure; the fall in weight was significant only in
the potassium group (P<0.05), and the fall in blood
pressure was significant only in the spironolactone
group (P<0.001). There was a significant fall in
plasma sodium (P<0.001) and a rise in bicarbonate
(P<0.01) in the spironolactone group. There was a
rise in blood urea in the amiloride group (P<0.01)
but no significant change in the plasma creatinine.
Red cell potassium did not change in any group.

Discussion
This longitudinal study was undertaken because
the previous cross-sectional study of patients with
heart failure had failed to detect large potassium
deicits and was therefore at variance with numerous
previous reports (Davidson et al., 1976). The patients
in the present study had apparent deficits which
were similar to those in the previous study (50–200
mmol). However, extra potassium, spironolactone
or amiloride failed to raise the total body or red cell
K despite a rise in plasma potassium, which makes
it unlikely they were potassium depleted.

There have been several similar studies in heart
failure in which either extra potassium or a potas-
sium-sparing diuretic has been added to the diuretic
<table>
<thead>
<tr>
<th>Group</th>
<th>No.</th>
<th>M</th>
<th>F</th>
<th>Age (Years)</th>
<th>Weight (kg)</th>
<th>Diagnosis*</th>
<th>Symptoms†</th>
<th>Treatment Furosemide (mg/day)</th>
<th>Treatment K mmol/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potassium supplements</td>
<td>13</td>
<td>5</td>
<td>8</td>
<td>59·2 (5·8)</td>
<td>60·2 (10·1)</td>
<td>7</td>
<td>3</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>16</td>
<td>5</td>
<td>11</td>
<td>54·4 (9·5)</td>
<td>64·7 (11·5)</td>
<td>11</td>
<td>3</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>Amiloride</td>
<td>20</td>
<td>10</td>
<td>10</td>
<td>54·8 (12·1)</td>
<td>69·4 (16·5)</td>
<td>13</td>
<td>7</td>
<td>0</td>
<td>18</td>
</tr>
</tbody>
</table>

* RHD – rheumatic heart disease; IHD – ischaemic heart disease; C – cardiomyopathy.
† Symptoms graded according to New York Heart Association criteria.
<table>
<thead>
<tr>
<th>Time</th>
<th>Blood pressure</th>
<th>Weight</th>
<th>Predicted</th>
<th>TRK</th>
<th>RBC</th>
<th>K (mmol/l)</th>
<th>TRK</th>
<th>K (mmol/l)</th>
<th>Na (mmol/l)</th>
<th>HCO₃⁻</th>
<th>Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
<tr>
<td>12.5</td>
<td>119.5</td>
<td>9.6</td>
<td>75</td>
<td>310</td>
<td>181</td>
<td>48</td>
<td>327</td>
<td>11.8</td>
<td>13.1</td>
<td>270.1</td>
<td>7.34</td>
</tr>
</tbody>
</table>

**Table 2.** The results before (0) and after 4 months treatment in the three groups of patients (mean and standard deviation).
Potassium status in heart failure

409

regime. Most studies have used exchangeable potassium (K_e) as a measure of body potassium. They have often involved small numbers of patients followed for relatively short periods, and the results have been conflicting.

Three groups have studied the effect of potassium supplements. De Deuchaisnes et al. (1961) gave eight patients 40–120 mmol/day of extra potassium for one to three weeks. The average K_e did not change and the extra potassium was excreted in the urine. White (1970) gave seven patients with heart failure and an apparent potassium deficit 48 mmol/day of extra potassium for 4 weeks. There was no change in plasma potassium but K_e increased by an average of 200 mmol. Down, Polak and Rao (1972) gave four patients with heart failure and an apparent potassium deficit 48 mmol/day for 2 months. There was no change in plasma potassium or K_e.

The results from studies of potassium-sparing diuretics have been equally inconclusive. Davidson and Gillebrand (1973) gave amiloride for 6 months to twenty-four patients with heart failure stabilized on furosemide. There was a sustained rise in plasma potassium; K_e initially rose by 320 mmol but at 6 months was no greater than before the change in treatment. Nicholls, Espiner and Hughes (1976) studied eleven patients with heart failure for 2 months after substituting amiloride for potassium supplements. There was no change in plasma potassium or K_e. White (1969) reported that spironolactone prevented any fall in K_e in patients taking furosemide; Friis (1972) concluded that it did not increase K_e in patients with heart failure. There are several studies showing that spironolactone increases plasma potassium (George, Breckenridge and Dollery, 1973).

The present study is thus in agreement with most reports from the literature. Extra potassium supplements or potassium-sparing diuretics can increase plasma potassium, but they do not influence body potassium. These drugs may therefore be unnecessary to maintain body potassium in heart failure during long-term diuretic treatment. Lawson Boddy and Gray (1976) gave twenty-one patients with heart failure diuretics but no potassium supplements for a year. There was a small fall in plasma potassium but no change in TBK.

Nevertheless, the general view is that patients with heart failure are depleted of potassium and that the depletion is related to the use of potent diuretics (Leading Article, 1977). This view seems to be based on the numerous reports of low K_e in patients with heart failure taking diuretics and the demonstration that these diuretics can increase the urine potassium and lower the plasma potassium. The authors have recently reviewed all published data on exchangeable potassium in patients with heart disease (Morgan, Burkinshaw and Davidson, 1978). Although there was an apparent deficit of 20–30% of body potassium, this deficit was no greater in the patients taking diuretics than in those who were not, and could be explained by the muscle wasting which happens in chronic heart disease.

The findings in the present study, the authors' previous study (Davidson et al., 1976), the study of Lawson et al. (1976) and the authors' review of the literature (Morgan et al., 1978) lead the authors to conclude that there is no true potassium depletion in patients with heart disease, even those taking diuretics. The only reason for treating patients with potassium supplements or potassium-sparing agents is to prevent or treat a low plasma potassium.

Acknowledgments

We are grateful to Dr W. Whitaker, Dr D. Smith and Mr M. Ionescu who allowed us to study their patients; Mrs D. Davidson who had a major responsibility in the organization of the study; Miss D. W. Krupowicz who made the TBK measurements; and Miss S. Hassam and the many staff of the Departments of Chemical Pathology who made the chemical measurements. The study was supported in part by a grant from G. D. Searle.

References


Friis, Th. (1972) In: Extrarenal Activity of Aldosterone and its Antagonists Excerpta Medica, Amsterdam, 35.


The effects of potassium supplements, spironolactone of amiloride on the potassium status of patients with heart failure.
C. Davidson, L. Burkinshaw and D. B. Morgan

Postgrad Med J 1978 54: 405-409
doi: 10.1136/pgmj.54.632.405

Updated information and services can be found at:
http://pmj.bmj.com/content/54/632/405

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/